These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27685911)

  • 1. Serum leptin levels may have diagnostic and predictive roles in patients with pancreatic adenocarcinoma treated with gemcitabine-based chemotherapy.
    Karabulut S; Usul Afsar C; Karabulut M; Alis H; Erturk K; Karaman S; Kones O; Bilgin E; Tas F
    J BUON; 2016; 21(4):895-902. PubMed ID: 27685911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma.
    Usul Afsar Ç; Karabulut M; Karabulut S; Alis H; Gonenc M; Dagoglu N; Serilmez M; Tas F
    J Infect Chemother; 2017 Apr; 23(4):196-200. PubMed ID: 28087305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma.
    Karabulut S; Afsar ÇU; Karabulut M; Alış H; Kılıc L; Çikot M; Yasasever CT; Aykan NF
    J Gastrointest Cancer; 2016 Mar; 47(1):47-54. PubMed ID: 26637231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
    An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
    Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
    Bauer TM; El-Rayes BF; Li X; Hammad N; Philip PA; Shields AF; Zalupski MM; Bekaii-Saab T
    Cancer; 2013 Jan; 119(2):285-92. PubMed ID: 22786786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine.
    Ploquin A; Truant S; Piessen G; Vuagnat P; Baldini C; Cattan S; Hebbar M
    In Vivo; 2017; 31(4):731-735. PubMed ID: 28652448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
    Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
    Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine.
    Ziske C; Schlie C; Gorschlüter M; Glasmacher A; Mey U; Strehl J; Sauerbruch T; Schmidt-Wolf IG
    Br J Cancer; 2003 Oct; 89(8):1413-7. PubMed ID: 14562009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer.
    Afsar CU; Karabulut M; Karabulut S; Ozal ST; Cikot M; Serilmez M; Tas F
    Biomolecules; 2018 Dec; 8(4):. PubMed ID: 30544746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
    Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
    Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating annexin A2 as a biomarker in patients with pancreatic cancer.
    Karabulut M; Afsar CU; Serilmez M; Karabulut S
    J Cancer Res Ther; 2020 Dec; 16(Supplement):S110-S115. PubMed ID: 33380663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.
    McCaffery I; Tudor Y; Deng H; Tang R; Suzuki S; Badola S; Kindler HL; Fuchs CS; Loh E; Patterson SD; Chen L; Gansert JL
    Clin Cancer Res; 2013 Aug; 19(15):4282-9. PubMed ID: 23741071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
    Saad ED; Machado MC; Wajsbrot D; Abramoff R; Hoff PM; Tabacof J; Katz A; Simon SD; Gansl RC
    Int J Gastrointest Cancer; 2002; 32(1):35-41. PubMed ID: 12630768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer.
    Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Furuse J; Inagaki M; Higashi S; Kato H; Terao K; Ochiai A
    Br J Cancer; 2013 May; 108(10):2063-9. PubMed ID: 23591198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy.
    Park I; Choi SJ; Kim YS; Ahn HK; Hong J; Sym SJ; Park J; Cho EK; Lee JH; Shin YJ; Shin DB
    Cancer Res Treat; 2016 Oct; 48(4):1264-1273. PubMed ID: 27034148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin.
    Heinemann V; Schermuly MM; Stieber P; Schulz L; Jüngst D; Wilkowski R; Schalhorn A
    Anticancer Res; 1999; 19(4A):2433-5. PubMed ID: 10470171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical features of long time survivors with unresectable pancreatic cancer treated by gemcitabine alone].
    Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Fujisawa N; Yoneda M; Abe Y; Inamori M; Kawamura H; Kirikoshi H; Shimamura T; Kubota K; Sakaguchi T; Saito S; Nakajima A
    Gan To Kagaku Ryoho; 2006 Feb; 33(2):207-12. PubMed ID: 16484857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
    Richards NG; Rittenhouse DW; Freydin B; Cozzitorto JA; Grenda D; Rui H; Gonye G; Kennedy EP; Yeo CJ; Brody JR; Witkiewicz AK
    Ann Surg; 2010 Sep; 252(3):499-505; discussion 505-6. PubMed ID: 20739850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of serum omentin-1 levels in patients with pancreatic adenocarcinoma.
    Karabulut S; Afsar CU; Karabulut M; Alis H; Bozkurt MA; Aydogan F; Serilmez M; Tas F
    BBA Clin; 2016 Dec; 6():138-142. PubMed ID: 27785418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
    Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.